Clinical trial · no report yet · Phase 3
CYCLONE 3
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
- NCT05288166 ↗
- Active not recruiting
- Eli Lilly and Company
- 7 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| Podcasts | 4 | |
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Prostatic Neoplasms; Neoplasm Metastasis; Urogenital Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Androgens; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Abiraterone Acetate; Steroid Synthesis Inhibitors; Cytochrome P-450; Enzyme Inhibitors; Prednisone; Prednisolone; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6
- Interventions
- Abemaciclib; Abiraterone; Prednisone or Prednisolone; Placebo for Abemaciclib
- Arms
- Abemaciclib · Experimental
- Placebo · Active comparator
- Enrollment
- 925
- Primary outcomes
- Radiographic Progression-Free Survival (rPFS) Assessed by Investigator
- Sponsor
- Eli Lilly and Company
- Start
- Apr 14, 2022
- Primary completion
- Feb 15, 2024
- Results posted
- Yes
- Registry record
- NCT05288166 · updated Jul 1, 2026